HC Wainwright Increases Earnings Estimates for CalciMedica

CalciMedica Inc. (NASDAQ:CALC) – Equities research analysts at HC Wainwright increased their Q3 2026 earnings per share (EPS) estimates for CalciMedica in a research report issued to clients and investors on Wednesday, August 12th. HC Wainwright analyst J. Pantginis now forecasts that the company will earn ($0.15) per share for the quarter, up from their prior forecast of ($0.36). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for CalciMedica’s current full-year earnings is ($1.35) per share. HC Wainwright also issued estimates for CalciMedica’s Q4 2026 earnings at ($0.17) EPS, FY2026 earnings at ($1.05) EPS, FY2027 earnings at ($0.63) EPS and FY2028 earnings at ($0.71) EPS.

CalciMedica (NASDAQ:CALC) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.17).

Several other research firms also recently weighed in on CALC. UBS Group reaffirmed a “neutral” rating on shares of CalciMedica in a research report on Thursday. Weiss Ratings raised shares of CalciMedica from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 29th. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $10.00.

CalciMedica Stock Performance

Shares of CALC stock opened at $0.66 on Friday. The firm’s 50 day moving average price is $0.81 and its 200-day moving average price is $0.78. CalciMedica has a one year low of $0.46 and a one year high of $7.20. The firm has a market cap of $10.39 million, a P/E ratio of -0.48 and a beta of 0.91.

Institutional Trading of CalciMedica

A number of large investors have recently bought and sold shares of the business. Boothbay Fund Management LLC acquired a new stake in CalciMedica during the 4th quarter worth approximately $506,000. Renaissance Technologies LLC grew its position in CalciMedica by 26.1% in the 4th quarter. Renaissance Technologies LLC now owns 88,300 shares of the company’s stock valued at $582,000 after buying an additional 18,300 shares during the last quarter. Jane Street Group LLC purchased a new position in CalciMedica in the 4th quarter valued at $127,000. Cetera Investment Advisers increased its stake in CalciMedica by 33.1% in the 2nd quarter. Cetera Investment Advisers now owns 36,385 shares of the company’s stock valued at $58,000 after buying an additional 9,045 shares during the period. Finally, Envestnet Asset Management Inc. increased its stake in CalciMedica by 58.2% in the 2nd quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock valued at $149,000 after buying an additional 34,386 shares during the period.

Insider Buying and Selling at CalciMedica

In related news, Director Fred A. Middleton purchased 248,972 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The shares were purchased at an average cost of $0.80 per share, for a total transaction of $199,177.60. Following the purchase, the director directly owned 1,063,272 shares of the company’s stock, valued at $850,617.60. The trade was a 30.57% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 28.25% of the company’s stock.

About CalciMedica

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.